Congress Program (last updated March 14, 2024)

THURSDAY, MARCH 21, 2024
8:00 – 10:00 and 16:00 – 18:00 | Registration at W SANTIAGO

FRIDAY, MARCH 22, 2024
07:00 – 17:00 | Registration at W SANTIAGO

FRI | 08:30 – 09:15 | Opening Ceremony
- Welcome Address
  Horacio Amaral, Vasko Kramer, Richard Baum, Frank Rösch (all TWC), Helen Nadel (SNMMI, USA), Aruna Korde (IAEA, Austria)
- Cultural Performance
  Ballet Folclorico (Chile)

FRI | 09:15 – 10:00 | Opening Lecture
- „Searching for our cosmic origins - A decade of molecular spectroscopy with ALMA“
  Sergio Martin (ALMA Observatory)

FRI | 10:00 – 10.30 | COFFEE BREAK. VISIT OF EXHIBITION.

FRI | 10:30 – 11:15 | Patient Access Session – Panel Discussion
Moderator: Dr. Cristiana Gameiro (Oncidium Foundation Advisor)
Radiotheranostics Global Access: Discussion with Patients and Experts
- "Building hope: navigating through the challenges and barriers to treatment access"
Supported by ICPO and Oncidium foundations

FRI | 11:15 – 12:00 | Healthcare System Readiness for RLT – Panel Discussion
Moderator: Prof. Dr. Richard Baum (ICPO/Curanosticum)
A multi-stakeholder panel discussion around key barriers and about how to tackle the increasing number of patients eligible for RLT
The potential of RLT in cancer care in the next 10 years: Call to action for Healthcare Systems Readiness

FRI | 12:00 – 13.30 | LUNCH BREAK. E-POSTER VIEWING. VISIT OF EXHIBITION.

FRI | 13:30 – 15:00 | Neuroendocrine Tumors & others

Chairs: Mariela Agolti (Nuclear Medicine Center Clinica Modelo, Argentina), Mike Sathekge (University of Pretoria, South Africa)

- 20 years’ experience with 177Lu DOTATATE: From “one fits all concept” to a personalized PPRT in neuroendocrine tumors
  Giovanni Paganelli (European Institute of Oncology, Italy)
- Pediatric Theranostics: A blueprint for the future
  Helen Nadel (Stanford, USA)
- Specific binding of SSTR2-targeting PRRT agonists and antagonists to human bone marrow stem cells provide insights into their distinct hematotoxicity profiles
  Susanne Kossatz (TU Munich, Germany)
- Latest updates in Targeted Alpha Therapy (TAT) using 212Pb-DOTAMTATE for the treatment of metastatic SSTR-expressing neuroendocrine tumors, in PRRT naïve and progressed patients
  Ebrahim Delpassand (RadioMedix / Excel Diagnostics, USA)
- SSTR2 antagonists for diagnosis and therapy of neuroendocrine tumors – from instant kit-type attempts to alpha therapy
  Lukas Greifenstein (Curanosticum, Germany)
- Developments towards the clinical translation of CCK-R2 ligands for imaging and therapy of various cancers
  Thomas Günter (UCSF Stanford, USA)

FRI | 15:00 – 15:30 | COFFEE BREAK. E-POSTER VIEWING. VISIT OF EXHIBITION.

FRI | 15:30 – 17:30 | Prostate Cancer

Chairs: Carlos Buchpiguel (University of Sao Paolo, Brasil), Elba Echtebehere (Universidade Estadual de Campinas, Brasil)

- Prostate Cancer & PSMA-targeted Theranostics
  Matthias Eiber (Technische Universität München, Germany)
- Psma Lu177: Randomized trials overview
  Oliver Sartor (Mayo Clinic, USA)
- New PSMA Theranostics
  Jae Min Jeong (Seoul National University, South Korea)
- 225Ac-PSMA RLT of advanced prostate cancer
  Mike Sathekge (University of Pretoria, South Africa)
- 225Ac-PSMA-617 Alpha Therapy: Current status in treating aggressive prostate cancer
  Chandrasekhar Bal (AIIMS, New Delhi, India)
[177Lu]Lu-LF1: A Gastrin releasing peptide receptor radioantagonist with great promise in advancing prostate cancer treatment  
Eleni Gourni (Inselspital Bern, Switzerland)

A Decade of GRPR PET Imaging – "Where are we and where are we going"?  
Andrei Iagaru (Stanford, USA)

FRI | 17:00 – 17:30 | ProsTIC24 Recap

- ProsTIC24 Recap  
  Michael Hofman (PeterMac, Australia)

FRI | 17:30 – 18:30 | Poster Session

19:00 – 20:00 TRANSPORT TO EVENT

FRI | 19:30 – 0:00 | Festive Evening* including AWARD CEREMONY

Indulge in an evening of networking and camaraderie at VISTA SANTIAGO for our Social Evening event!

Award Ceremony
- Saul Hertz Young Investigator Award (presented by Barbara Hertz)
- Edwaldo E. Camargo Young Investigator Award (presented by Elba Etchebehere Camargo)
- Jorge Nicolini Young Investigator Award (presented by Mariano E. Nicolini)

*Must be booked additionally.
SATURDAY, MARCH 23, 2024

07:30 – 17:00 | Registration at W SANTIAGO

SAT | 08:30 – 10:00 | Medical Physics & Instrumentation

Chairs: Danny Mena Cortes (Hospital Angeles Lomas, Mexico), Wolfgang Weber (TU Munich, Germany)

- Whole-body PET/CT and what it can contribute to the development of new theranostic approaches
  Simon Cherry (UC Davis, USA)
- A framework to engage the imaging community in advancing total-body PET
  Thomas Beyer (University Vienna, Austria)
- Knowledge-guided artificial intelligence for personalized nuclear medicine theranostics
  Kuangyu Shi (University of Bern, Switzerland)
- Alpha-Particle Dosimetry
  Bryan Bednardz (Univ. Wisconsin, USA)
- Transforming theranostics: integration of ai and machine learning for precision molecular imaging
  Harshad Kulkarni (BAMF, USA)

---

Panel Discussion
Moderation: Thomas Beyer

SAT | 10:00-10:30 | COFFEE BREAK. E-POSTER VIEWING. VISIT OF EXHIBITION.

SAT | 10:30 – 13:30 | Presentations by the Industry

<table>
<thead>
<tr>
<th>Timing</th>
<th>Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 – 11:45</td>
<td>Industry Session I</td>
</tr>
<tr>
<td></td>
<td>3B Pharmaceuticals GmbH</td>
</tr>
<tr>
<td></td>
<td>FAP: THERAPY, IMAGING, AND BEYOND</td>
</tr>
<tr>
<td></td>
<td>Development of a novel FAP molecule for radioligand therapy</td>
</tr>
<tr>
<td></td>
<td>Dr. Lindsey Rolfe and Dr. Christiane Smerling, 3BP</td>
</tr>
<tr>
<td></td>
<td>SCINTIX biology-guided radiotherapy with RXM-5201</td>
</tr>
<tr>
<td></td>
<td>Dr. Thorsten Melcher, RefleXion Medical</td>
</tr>
<tr>
<td></td>
<td>SPECTROFAP – FAP imaging for SPECT</td>
</tr>
<tr>
<td></td>
<td>Dr. Jan Lennart von Hacht, 3BP</td>
</tr>
<tr>
<td>12:15 – 12:45</td>
<td>Industry Session II</td>
</tr>
<tr>
<td></td>
<td>Novartis</td>
</tr>
</tbody>
</table>
HOW PARTNERSHIPS CAN SUPPORT INNOVATION & EVOLUTION OF RLT IN THE FUTURE

- Introductions & setting the stage on RLT potential across solid tumors
  Jeevan Virk, Therapeutic Area Strategy Head, RLT, Novartis
- Fire-side chat with representatives
  Michael Hofman; Chandrasekhar Bal; Mike Sathekge

1. RLT has the potential to become the essential future pillar of cancer care and numerous CTs are ongoing across various solid tumors; which are the barriers to enter and what are the potential solution to speed up development by using the unique properties of RLT?
2. How can we educate our respective stakeholders to get the RLT innovation to all eligible patients timely? Are there any other stakeholders that we need to involve?
3. What does the 10-year vision for RLT look like?

13:00 – 13:30  Industry Session III
ITM Isotope Technologies Munich SE

- Emitting Excellence: Illuminating the evolving landscape of Radiopharmaceutical Therapy
  From 2004 to 2024, ITM has evolved from a company which has developed and commercialized no carrier added 177Lu into a fully-fledged radiopharmaceutical company with a robust radiotheranostic pipeline.
  Join us to discuss the journey from radioisotope production to the treatment of patients with neuroendocrine tumors and other oncology conditions and find out how these advancements are shaping therapeutic outcomes and paving the way for a brighter future in healthcare.

SAT | 13:30 – 15:00 | Novel Targets & Chemistry
Chairs: Rene Leyva Montana (CENTIS, Cuba), Jan Rijn Zeevaart (Necsa, South Africa)

- Recent progress of integrin-targeted theranostics
  Jakub Simecek (Trimt, Germany)
- Imaging of CXCR4 expression in patients with hematologic neoplasms
  Andreas Buck Werner (University Hospital Würzburg, Germany)
- Emerging 68Ga-Pentixafor PET/CT Applications for targeting CXCR4 receptors in human cancers – An Indian experience
  Baljinder Singh (PGIMER, Chandigarh, India)
- 177Lu-LNC1011: Striking the balance of circulation half-life and tumor accumulation for prostate cancer therapy
  Shawn Chen (LNC, Singapore)
- 211At-PSMA for alpha-RLT of prostate cancer
  Matthias Herth (University of Copenhagen, Denmark)
- Novel targets beyond FAPI: HSP70, Gal3
  Wolfgang Weber (TU Munich, Germany)
SAT | 15:30 – 16:30 | TME Diagnostics
Chairs: Munir Ghesani (Mount Sinai Health System, USA), Andrew Scott (Department Of Molecular Imaging and Therapy, Austin Health, Australia)

- History and biology of FAP: implications for clinical use of new generation FAP-ligands
  Andrew Scott (Department Of Molecular Imaging And Therapy, Austin Health, Australia)
- Druglike, 18F-labeled PET tracers targeting fibroblast activation protein (FAP)
  Pieter van der Veken (University of Antwerp, Belgium)
- Overview of today’s clinical applications and perspectives
  Frederik Giesel (Heinrich Heine University Düsseldorf, Germany) – Online
- FAPI – Advancements in diagnostics
  Sherly Mossesian & Paul Evans (Sofie Bioscience & GEHC, USA)
- FAPI Diagnostics: clinical impact and future role of FAPI-PET
  Tadashi Watabe (Osaka University, Japan) – Online

SAT | 16:30 – 18:00 | TME Therapeutics
Chairs: Michael Kreisl (University Hospital Magdeburg, Germany), Elisabeth Eppard (University Hospital Magdeburg, Germany)

- Clinical applications and perspectives of 3BP-3940
  Richard P. Baum (Curanosticum; ICPO, Germany)
- FAPI-Dimers-Chemistry and preclinical evaluation
  Marcel Martin (TetraKit Technologies, Denmark)
- Assessing the long-term impact of FAP dimer therapy in cancer treatment
  Sanjana Ballal (AIIMS, New Delhi, India)
- Next generation 64Cu- and 225Ac-labelled radioligands for FAP-targeted therapy
  John Babich (Ratio Therapeutics, USA)
- Novel FAP-targeting small molecule radio-conjugates with high and prolonged tumour uptake
  Jacqueline Mock (Philochem, Switzerland) – Online
- Radiotheranostics with Dual Targeting Probe 68Ga-/18F-/177Lu-FAPI-RGD in diverse solid tumors
  Jingjing Zhang (University of Singapore, Singapore)

SAT | 18:00 – 18:20 | TME – Panel Discussion
Moderator: Frank Rosch (Johannes Gutenberg University Mainz, Germany)

- Panel Discussion about latest advancements in TME diagnostics, therapeutics, and ongoing developments
SUNDAY, MARCH 24, 2024
07:30 – 17:00 | Registration at W SANTIAGO

SUN | 8:00 – 9:15 | Current State of Isotope Production
Chairs: Aruna Korde (IAEA, Austria), Antero Abrunhosa (ICNAS, University of Coimbra, Portugal)

- **Current status of DOE Isotope Production Program for theranostic radionuclides**
  Cathy Cutler (Brookhaven National Laboratory, USA)
- **Current status of Canadian Isotope Production Program for theranostic radionuclides**
  Valery Radchenko (Triumf, University of British Columbia, Canada)
- **At-211: Recent progress in isotope production, pharmaceutical chemistry, clinical translation**
  Jean-Francois Gestin (COST, NOAR, France)
- **Pb203 Image Guided Pb212 Alpha Particle Therapy for cancer – A global solution for multiple indications**
  Michael Schultz (Perspective Therapeutics, USA)

SUN | 9:15 – 10:00 | Theranostic Pairs
Chairs: Katherine Gagnon (GE Healthcare, Sweden), Miguel Avila Rodriguez (UNAM, Mexico)

- **Cu-64/67: Recent progress in isotope production, pharmaceutical chemistry, clinical translation**
  Jason Lewis (MSKCC, USA)
- **Pb-203/212 & Sc-44/47: Recent progress in isotope production, pharmaceutical chemistry, clinical translation**
  Suzanne Lapi (University of Alabama, USA)
- **Y-86/90 & Sc-44: Recent progress in isotope production, pharmaceutical chemistry, clinical translation**
  Eduardo Aluicio Sarduy (Wisconsin Cyclotron Lab, USA)

SUN | 10:00 – 10:30 | COFFEE BREAK. E-POSTER VIEWING. VISIT OF EXHIBITION.

SUN | 10:30 – 13:30 | Presentations by the Industry

<table>
<thead>
<tr>
<th>Timing</th>
<th>Partner</th>
</tr>
</thead>
</table>
| 10:30 – 11:15   | **Industry Session IV**
                 | Siemens Healthineers                         |
|                 | t.b.a.                                       |
| 11:45 – 12:30   | **Industry Session V**
                 | Joint Symposium                              |

211AT INDUSTRIALS WITHIN THE WORLD ASTATINE COMMUNITY (WAC)
- **Introduction of WAC**
  Jean-Francois Gestin, Ethan Balkin, Kohshin Washiyama

- **Industrial presentations**
  Sumitomo Heavy industries (Taki Kazuya), Toshiba (Yasuhiro Suzuki), Ionetix (David Eve), Nusano (Gregory Moffitt), Atley Solutions (Milton Lönnroth), Tetrakit (Andreas Jensen), Astathera (Michael Zalutsky), Alpha fusion (Sunao Fujioka)

**12:45 – 13:05 Industry Session VI**
GE HealthCare International LLC

- **Building the future in theranostics**
  Dr. Carlos Buchpiguel, Head of Nuclear Medicine at Sirio Libanes Hospital, Brazil (First Omni Legend 32 user in LATAM)

**SUN | 13:30 – 15:00 | Novel Indication, Concepts & Genetics**
**Chairs: Rene Francisco Fernandez Belmar (Positronmed, Chile), Michael Hofman (PeterMac, Australia)**

- What doesn’t kill me makes me strong!
  Rodney Hicks (University of Melbourne and Monash University, Australia)

- uPAR Theranostics: Targeting the Invasive Phenotype
  Andreas Kjaer (University of Copenhagen, Denmark)

- Nanoparticle Enhanced Radioligand Therapy (NERT)
  Julie Constanzo (INSERM, Montpellier, France)

- Radionuclide Targeted Treatment for Glioma: Substance-P and PSMA
  Jolanta Kunikowska (Nuclear Medicine Department, Medical University of Warsaw, Poland)

- Paradigm shift in bladder cancer treatment: Theranostic incubator concept to treat chemotherapy resistant muscle-invasive bladder cancer
  Ralph Wirtz (Stratifyer, Germany)

- BRCA germline positive vs somatic BRCA and the impact on prostate cancer
  Masha Maharaj (South Africa, South Africa)

**SUN | 15:00 – 15:30 | COFFEE BREAK. E-POSTER VIEWING. VISIT OF EXHIBITION.**

**SUN | 15:30 – 17:00 | Combination Therapies**
**Chairs: Francois Lamoureux (Canadian Association of Nuclear Medicine, Canada), Rodney Hicks (University of Melbourne and Monash University, Australia)**

- Theranostics 2.0: Embracing the power of PSMA combinations
  Michael Hofman (PeterMac, Australia)

- Combining radioligand therapy and immune checkpoint inhibitors: preclinical rationale and ongoing clinical trials
  Patrick Flamen (Hôpital Universitaire de Bruxelles, Belgium)

- Combinatorial Theranostic targeting of tumors and the tumor microenvironment
  Michael Bachmann (FZ Dresden-Rossendorf, Germany)
GRPr Theranostics in prostate cancer
Bernd Krause (University Hospital Rostock, Germany) – Online

Immunostimulatory effects of targeted radioligand therapy
Jean Pierre Pouget (INSERM, Montpellier, France)

Enhancing the efficacy of theranostics with DNA damage repair inhibitors
Andrew Scott (Olivia Newton John Cancer Research Institute, Australia)

SUN | 17:00 – 17:30 | Closing Ceremony

Farewell & outlook for the next TWC
Horacio Amaral, Vasko Kramer, Richard Baum, Frank Rösch (all TWC)